Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 13/20 | 0.78 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2720521 | 0.90 | TRPM8 (0.81) | TRPM8NPC1L3MBTL1KDM4E | |
| SCHEMBL2720524 | 0.90 | TRPM8 (0.81) | TRPM8NPC1L3MBTL1KDM4E | |
| SCHEMBL17230204 | 0.89 | TRPM8 (0.69) | TRPM8NPC1L3MBTL1KDM4E | |
| SCHEMBL2718603 | 0.88 | TRPM8 (1.00) | TRPM8NPC1L3MBTL1 | |
| SCHEMBL2717965 | 0.88 | TRPM8 (0.82) | TRPM8NPC1L3MBTL1KDM4E | |
| SCHEMBL2718605 | 0.88 | TRPM8 (1.00) | TRPM8NPC1L3MBTL1 | |
| SCHEMBL2717967 | 0.88 | TRPM8 (0.82) | TRPM8NPC1L3MBTL1KDM4E | |
| SCHEMBL2717146 | 0.86 | TRPM8 (0.80) | TRPM8NPC1L3MBTL1 | |
| SCHEMBL10168528 | 0.86 | TRPM8 (0.80) | TRPM8NPC1L3MBTL1 | |
| SCHEMBL2717150 | 0.86 | TRPM8 (0.80) | TRPM8NPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953007-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2021-03-23 | — | — | US | disclosed |
| US-10016418-B2 | Compounds useful as modulators of TRPM8 | Seaomyx, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016418-B2 | Compounds useful as modulators of TRPM8 | Seaomyx, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180055069-A1 | PREPARATIONS | SYMRISE AG (DE) | 2018-03-01 | — | — | US | disclosed |
| US-20180049449-A1 | PREPARATIONS | SYMRISE AG (DE) | 2018-02-22 | — | — | US | disclosed |
| US-20160317532-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2016-11-03 | — | — | US | disclosed |
| US-20160317532-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2016-11-03 | — | — | US | disclosed |
| US-9394287-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394287-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150313820-A1 | PREPARATIONS | SYMRISE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150313820-A1 | PREPARATIONS | SYMRISE AG (DE) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953007-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPM6 | TRPM8 1/4885NPC1 1050/4885L3MBTL1 4024/4885 |
| US-10016418-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPM6 | TRPM8 1/4885NPC1 1050/4885L3MBTL1 4024/4885 |
| US-20160317532-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM7, TRPM6 | TRPM8 1/4885NPC1 1050/4885L3MBTL1 4024/4885 |
| US-20180049449-A1 | PREPARATIONS | CRAT, ACAT2, TAS2R50 | TRPM8 101/4885NPC1 2008/4885L3MBTL1 4348/4885 |
| US-20180055069-A1 | PREPARATIONS | CRAT, ACAT2, TAS2R50 | TRPM8 101/4885NPC1 2008/4885L3MBTL1 4348/4885 |
| US-20150313820-A1 | PREPARATIONS | CRAT, ACAT2, TAS2R50 | TRPM8 101/4885NPC1 2008/4885L3MBTL1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.